A Multi-center Retrospective Study With Secondary Use of Data of Tafinlar (Dabrafenib) Plus Mekinist (Trametinib) in Chinese Patients With BRAF V600 Mutation Positive Melanoma

Conditions: BRAF V600 Mutation Positive Melanoma Sponsors: Novartis Pharmaceuticals Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials